3-(4'-aminobenzoyl)-8-Boc-3,8-diazabicyclo[3.2.1]octane | 401514-16-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4'-aminobenzoyl)-8-Boc-3,8-diazabicyclo[3.2.1]octane
• 英文别名: Tert-butyl 3-(4-aminobenzoyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
• CAS: 401514-16-7
• 化学式: C₁₈H₂₅N₃O₃
• 分子量: 331.415
• InChiKey: SCFFAHMZMUPUMB-UHFFFAOYSA-N

物化性质

• 沸点：
  515.2±45.0 °C(Predicted)
• 密度：
  1.220±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  75.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4'-aminobenzoyl)-8-Boc-3,8-diazabicyclo[3.2.1]octane 在 盐酸 作用下， 以 乙醚 为溶剂， 以90%的产率得到3-(4'-aminobenzoyl)-3,8-diazabicyclo[3.2.1]octane
  参考文献：
  名称：

  3,8-Diazabicyclo-[3.2.1]-octane derivatives as analogues of ambasilide, a Class III antiarrhythmic agent

  摘要：

  Ambasilide, a representative of Class III antiarrhythmics, was reported to prolong the cardiac action potential duration in the dog, with little or no effect on Ca and Na currents. We synthesised a series of ambasilide analogues, having the 3,8-diazabicyclo-[3.2.1]-octane moiety instead of the 3,7-diazabicyclo-[3.3.1]-nonane present in ambasilide. The compounds were tested both in vitro extracellular electrophysiological assays and by the conventional microelectrode technique. Most of them lengthened the effective refractory period (ERP) with no change or slight increase on the impulse conduction time (ICT). Similarly some of the tested compounds lengthened the action potential duration (APD), a typical Class III feature, without exerting any significant effect on the maximal rate of depolarization, therefore apparently lacking Class I antiarrythmic activity. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(01)01246-6
• 作为产物：
  描述：

  8-BOC-3,8-二氮杂双环[3.2.1]辛烷 、 4-氨基苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以60%的产率得到3-(4'-aminobenzoyl)-8-Boc-3,8-diazabicyclo[3.2.1]octane
  参考文献：
  名称：

  3,8-Diazabicyclo-[3.2.1]-octane derivatives as analogues of ambasilide, a Class III antiarrhythmic agent

  摘要：

  Ambasilide, a representative of Class III antiarrhythmics, was reported to prolong the cardiac action potential duration in the dog, with little or no effect on Ca and Na currents. We synthesised a series of ambasilide analogues, having the 3,8-diazabicyclo-[3.2.1]-octane moiety instead of the 3,7-diazabicyclo-[3.3.1]-nonane present in ambasilide. The compounds were tested both in vitro extracellular electrophysiological assays and by the conventional microelectrode technique. Most of them lengthened the effective refractory period (ERP) with no change or slight increase on the impulse conduction time (ICT). Similarly some of the tested compounds lengthened the action potential duration (APD), a typical Class III feature, without exerting any significant effect on the maximal rate of depolarization, therefore apparently lacking Class I antiarrythmic activity. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(01)01246-6

文献信息

• BMP-SIGNAL-INHIBITING COMPOUND
  申请人：RIKEN

  公开号：US20190337926A1

  公开（公告）日：2019-11-07

  The present invention relates to novel and excellent small-molecule-corn pounds that specifically antagonize BMP signal pathways, and these compounds can be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus can be used to treat diseases or pathological symptoms related to BMP signal pathway including inflammation, cardiovascular diseases, hematopoietic diseases, cancer, osteodystrophia, or the like, particularly, fibrodysplasia ossificans progressiva, and the present invention relates to provision of a pharmaceutical and pharmacological agent used for specifically antagonizing the BMP signal pathways and acting on the BMP signal pathways in the prevention and treatment or experimental application since the compounds can be beneficial for regulating cell differentiation and/or cell proliferation.

  本发明涉及一种新颖且优秀的小分子化合物，可以特异性拮抗BMP信号通路，这些化合物可用于调节细胞生长、分化、增殖和凋亡，因此可用于治疗与BMP信号通路相关的疾病或病理症状，包括炎症、心血管疾病、造血系统疾病、癌症、骨发育不良等，特别是纤维性骨化进行性疾病。本发明涉及提供一种用于特异性拮抗BMP信号通路并作用于BMP信号通路的药物和药理剂，用于预防和治疗或实验应用，因为这些化合物有助于调节细胞分化和/或细胞增殖。
• BMP-signal-inhibiting compound
  申请人：RIKEN

  公开号：US10954216B2

  公开（公告）日：2021-03-23

  The present invention relates to novel and excellent small-molecule-compounds that specifically antagonize BMP signal pathways, and these compounds can be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus can be used to treat diseases or pathological symptoms related to BMP signal pathway including inflammation, cardiovascular diseases, hematopoietic diseases, cancer, osteodystrophia, or the like, particularly, fibrodysplasia ossificans progressiva, and the present invention relates to provision of a pharmaceutical and pharmacological agent used for specifically antagonizing the BMP signal pathways and acting on the BMP signal pathways in the prevention and treatment or experimental application since the compounds can be beneficial for regulating cell differentiation and/or cell proliferation.

  本发明涉及特异性拮抗BMP信号通路的新型优良小分子化合物，这些化合物可用于调节细胞生长、分化、增殖和凋亡，从而可用于治疗与BMP信号通路相关的疾病或病理症状，包括炎症、心血管疾病、造血疾病、癌症、骨营养不良症、本发明涉及提供一种用于特异性拮抗 BMP 信号通路并作用于 BMP 信号通路的药物和药理制剂，以预防和治疗或实验应用，因为该化合物可有益于调节细胞分化和/或细胞增殖。